DAR File No.: 29629
Filed: 03/12/2007, 09:54
Received by: NLRULE ANALYSIS
Purpose of the rule or reason for the change:
This amendment is necessary to continue the provision of medically necessary and cost effective transplant services for Medicaid clients.
Summary of the rule or change:
This change clarifies and amends transplant service coverage and prior authorization criteria. It also clarifies and amends criteria for transplantation centers or facilities, criteria for cornea transplantation, criteria for bone marrow transplantation, criteria for heart transplantation, criteria for intestine transplantation, criteria for kidney transplantation, criteria for liver transplantation, criteria for lung transplantation, criteria for pancreas transplantation, criteria for small bowel transplantation, criteria for heart and lung transplantation, criteria for intestine and liver transplantation, criteria for kidney-pancreas transplantation, criteria for liver-kidney transplantation, criteria for multivisceral transplantation, and criteria for liver and small bowel transplantation.
State statutory or constitutional authorization for this rule:
Anticipated cost or savings to:
the state budget:
There is an estimated annual cost of $89,100 to the General Fund and $210,900 in federal funds to pay for transplant services.
local governments:
There is no budget impact because local governments do not fund transplant services and remain unaffected by the transplant rule changes.
other persons:
There is estimated revenue of $300,000 to hospitals and transplant centers based on an estimate of two organ transplants per year.
Compliance costs for affected persons:
There is estimated revenue of $150,000 to a single hospital or transplant center based on an average of one organ transplant per year.
Comments by the department head on the fiscal impact the rule may have on businesses:
The fiscal impact on regulated businesses and Medicaid recipients should be positive. Liver and heart transplant centers in Utah that have Medicare certification will not have to individually justify proposed transplants. Medicaid recipients will see faster approval of transplants and the resulting improvement in quality of life. David N. Sundwall, MD, Executive Director
The full text of this rule may be inspected, during regular business hours, at the Division of Administrative Rules, or at:
Health
Health Care Financing, Coverage and Reimbursement Policy
CANNON HEALTH BLDG
288 N 1460 W
SALT LAKE CITY UT 84116-3231Direct questions regarding this rule to:
Craig Devashrayee at the above address, by phone at 801-538-6641, by FAX at 801-538-6099, or by Internet E-mail at cdevashrayee@utah.gov
Interested persons may present their views on this rule by submitting written comments to the address above no later than 5:00 p.m. on:
05/01/2007
This rule may become effective on:
05/09/2007
Authorized by:
David N. Sundwall, Executive Director
RULE TEXT
R414. Health, Health Care Financing, Coverage and Reimbursement Policy.
R414-10A. Transplant Services Standards.
R414-10A-2. Definitions.
For purposes of Rule R414-10A:
(1) "Abstinence" means the documented non-use of any abusable psychoactive substance by the client with random monthly drug screen tests.
(2) "Active infection" means current presumptive evidence of invasion of tissue or body fluids by bacteria, viruses, fungi, rickettsiae, or parasites which is not demonstrated to be effectively controlled by the host, antibiotic or antimicrobial agents.
(3) "Age group" means patients documented in the medical literature with an age at the time of transplantation related to the current age of the client as listed below:
(a) Birth through 12 months;
(b) One through 12 years;
(c) 13 through 20 years;
(d) 21 through 30 years;
(e) 31 through 40 years; or
(f) 41 through 54 years.
(g) Department medical consultants may consider other age groups, documented by the medical literature and the transplant center to have conclusive relevance to the client's survival.
(4) "Active substance abuse" means the current use of any abusable psychoactive substance which is not appropriately prescribed and taken under the direction of a physician or is not medically indicated.
(5) "Allogenic" means having a different genetic constitution but belonging to the same species.
(6) "Autologous" means the products or components of the same individual person.
(7) "Bone marrow transplantation" means transplantation of cells from the bone marrow stem cells, peripheral blood stem cells, or cord blood stem cells to supplant the client bone marrow.
([
7]8) "Client" means an individual eligible to receive covered Medicaid services from an enrolled Medicaid provider.([
8]9) "Department" means the Utah Department of Health.(10) "Donor lymphocyte infusion" means infusion of allogenic lymphocytes into the client.
(11) "Drug screen" means random testing for tobacco, marijuana, alcohol, benzodiazepines, narcotics, methadone, cocaine, amphetamines, and barbiturates.
([
9]12) "Emergency transplantation" means any transplantation which for reasons of medical necessity requires that a transplant be performed less than five days after determination of the need for the procedure.(1[
0]3) ["Increase in life expectancy" means the difference in the average number of years of life between the life expectancy of the control group of patients compared to the life expectancy of the transplantation group.(11)]"Intestine transplantation" means transplantation of both the small bowel and colon.[(12) "Life expectancy" means the average number of years of life remaining for the age group of the client at the time the Department receives the prior authorization request.](1[
3]4) "Medical literature" means articles and medical information which have been peer reviewed and accepted for publication or published.(1[
4]5) "Medically necessary" means a client's medical condition which meets all the criteria and none of the contraindications for the type of transplantation requested.(1[
5]6) "Multiple transplantations" means, except for corneas, the transplantation of more than one tissue or organ during the same or different operative procedure.(1[
6]7) "Multivisceral transplantation" means the transplantation of liver, pancreas, omentum, stomach, small intestine and colon.(1[
7]8) "Patient" means a person who is receiving covered professional services provided or directed by a licensed practitioner of the healing arts enrolled as a Medicaid provider.(1[
8]9) "Remission" means the lack of any evidence of the leukemia on physical examination and hematological evaluation, including normocellular bone marrow with less than five percent blast cells, and peripheral blood counts within normal values, except for clients who are receiving maintenance chemotherapy.([
19]20) "Services" means the type of medical assistance specified in sections 1905(a)(1) through (24) of the Social Security Act and interpreted in the 42 CFR Section 440, Subpart A, October 1992 edition, which is adopted and incorporated by reference.(2[
0]1) "Substance abuse rehabilitation program" means a rehabilitation program developed and conducted by an inpatient facility that, at a minimum, meets the standards of organization and staff of a chemical dependency/substance abuse specialty hospital specified in Sections R432-102-4[,] and 5.(2[
1]2) "Syngeneic" means possessing identical genotypes, as monozygotic or identical twins.(2[
2]3) "Transplantation" means the transfer of a human organ or tissue from one person to another or from one site to another in the same individual, except for skin, tendon, and bone.(2[
3]4) "Vital end-organs" means organs of the body essential to life, e.g., the heart, the liver, the lungs, and the brain.R414-10A-3. Client Eligibility Requirements for Coverage for Transplantation Services.
Transplantation services are available to categorically eligible and medically needy individuals who are Title XIX eligible and meet criteria listed in Sections R414-10A-6 through 22 at the time the transplantation service is provided.
R414-10A-4. Program Access Requirements.
(1) Transplantation services may be provided only for those eligible clients who meet the criteria listed in Sections R414-10A-6 through 22 for services covered under the Utah Medicaid program.
(2) Transplantation services for the organ needed by the client may be provided only in a transplant center approved by the United States Department of Health and Human Services as a Medicare designated center or by the Department in accordance with criteria in Section R414-10A-7.
(3) Transplantation services may be provided out-of-state only when the authorized service is not available in an approved facility in the state of Utah.
(4) Criteria listed in Rule R414-10A applicable to transplantation services and transplant centers in the state of Utah also apply to out-of-state transplant services and facilities.
(5) Post transplant authorization for transplantation services provided under [
unusual,]emergency circumstances may be given only when:(a) all Utah Medicaid criteria listed in Sections R414-10A-6 through 22 are met; and
(b) both the transplant center and the board-certified or board-eligible specialist evaluation required by Subsection R414-10A-6(3)[
(f), (p), (q), and (r)] are submitted with the recommendation that the tissue or organ transplantation be authorized.R414-10A-5. Service Coverage.
(1) Transplantation services are covered by the Utah Medicaid program only when criteria listed in Sections R414-10A-6 through 22 are met.
(2) Transplantations which are experimental or investigational or which are performed on an experimental or investigational basis are not covered.
(3) Multiple transplantation services may be provided only when the criteria for the specific multiple transplantations are met.
(4) Staff shall not consider criteria for single tissue or organ transplantation in reviewing requests for multiple transplantations.
(5) Transplantation of additional tissues or organs, different from prior transplantations, may be provided only when the criteria for multiple transplantations of all provided or scheduled multiple tissue or organ transplantations are met.
(6) The Utah Medicaid program covers [
R]repeat transplantations of the same tissues or organs [may be provided]only when [documentation reviewed by Department staff and medical consultants shows that criteria for transplantation of the specific tissues or organs are met]the Department approves a new prior authorization under criteria found in Sections R414-10A-6 through 22.(7) Payment for [
E]emergency transplantations may be provided only when the service is provided for a transplantation with criteria approved in Sections R414-10A-6 through 22. Payment will not be made until Department staff has reviewed all of the information required by Sections R414-10A-6 through 22 and determined that the patient and the transplant center met criteria for approval and provision of the service at the time of the transplantation.(8) The Utah Medicaid program does not cover the following transplantation services:
(a) Beta cells or other pancreas cells not part of a pancreatic organ transplantation.
(b) Cells or tissues transplanted into the coronary arteries, myocardium, central nervous system, or spinal cord.
(c) Stem cells other than hematological stem cells.
(d) Donor lymphocyte infusions for clients who have not had a prior bone marrow transplantation.
(9) The Utah Medicaid program does not cover the following procedures:
(a) Temporary or implanted ventricular assist devices with the exception of intra-aortic balloon assist devices.
(b) Temporary or implanted biventricular assist devices.
(c) Temporary or implanted mechanical heart.
R414-10A-6. Prior Authorization.
(1) Prior authorization is required for all transplantation services except for [
cornea and kidney transplantation.]the following transplants:(a) cornea transplantation.
(b) kidney, heart and liver transplantation performed in a Utah transplant center, which has been Medicare-approved for the last five or more years.
(2) The prior authorization request for transplantation services must be initiated by the client's referring physician. Failure to submit all required information with the prior authorization request will delay processing of the request for transplantation.
(3) The initial request for prior authorization of any transplantation, except cornea or kidney, must contain all of the following:
(a) [
A request for Prior Authorization Form 24-06-37, completed and signed by the physician.(b)]A description of the medical condition which necessitates a transplantation.[(c) Medical literature from the transplant center documenting the client's life expectancy, with and without a transplant. The transplant center staff must complete and submit to the Department for staff review and evaluation, a medical literature review documenting a probability of successful clinical outcome for patients receiving transplantation for the specific age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. This review of the medical literature must document an increase in life expectancy between control group(s) and transplantation group(s). The Department shall use independent research by medical consultant(s) to evaluate the documentation submitted by the transplant center.]([
d]b) Transplantation treatment alternatives utilized previous to the transplantation request.([
e]c) Transplantation treatment alternatives considered and discarded, including discussion of why the alternatives have been discarded.([
f]d) Comprehensive examination, evaluation and recommendations completed by a board-certified or board-eligible specialist in a field directly related to the client's condition which necessitates the transplantation, such as a nephrologist, gastroenterologist, cardiologist, or hematologist.([
g]e) Comprehensive psycho-social evaluation of the client [by a board-certified or board-eligible psychiatrist. The evaluation]must include a comprehensive history regarding substance abuse and compliance with medical treatment.([
h]f) Psycho-social evaluation of parent(s) or guardian(s) of the client, [by a board-certified or board-eligible psychiatrist]if the client is less than 18 years of age. The psycho-social evaluation must include a comprehensive history regarding substance abuse, and past and present compliance with medical treatment.([
i]g) Comprehensive psychiatric evaluation of the client, if the client has a history of mental illness.([
j]h) Comprehensive psychological or developmental testing, as requested by the Department.([
k]i) Comprehensive infectious disease evaluation for a client with a recent or current suspected infectious episode.([
l]j) Documentation by the client's referring physician that a client with a history of substance abuse has successfully completed a substance abuse program or has documented abstinence for a period of at least six months before any transplantation service can be authorized.(k) At least two negative drug screens within three months of the request date for prior authorization. The Utah Medicaid program requires monthly drug screens until the transplant date or until the transplant is denied if either of the two random drug screens are positive for drug use, past drug screens have been positive for drug use, or the Department requests the monthly screens. If the client has a history of substance abuse that does not include the drugs listed in Subsection R414-10A-2(11), then the drug screens must include the other substance(s) upon drug testing availability.
([
m]l) Hospital and outpatient records for at least the last two years, unless the patient is less than two years of age, in which case all records.(m) Pretransplant evaluation for a client diagnosed with cancer that includes staging of the cancer, laboratory tests, and imaging studies. A letter documenting that the transplant evaluation has been completed and that all medical records documentation from the evaluation have been transmitted to the Department.
(n) Any other medical evidence needed to evaluate possible contraindications for the type of transplantation being considered. Contraindications are listed in this rule under each organ or transplant type.
(o) The transplant center must document, by a current medical literature review, a one-year survival rate from patients having received transplantation for the age group, specific diagnosis(es), condition and type of transplantation proposed for the client. Survival rate must be calculated by the Kaplan-Meier product-limit method or the actuarial life table method: "Kaplan, G., Meier, P. Non-Parametric estimation from incomplete observations. Journal of American Statistical Association 53:457-481, 1958. Cox, D.R., Oakes, D. Analysis of survival data. Chapman and Hill, 1984." adopted and incorporated by reference. At least ten patients in the appropriate age group must be alive at the end of the one or three year period to document adequate confidence intervals. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(p) The transplant center must document by a current medical literature review, a one year graft function rate for patients having received pancreas, kidney or small bowel transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. Graft function rate must be calculated by the Kaplan-Meier product-limit method or the actuarial life table method: "Kaplan, G., Meier, P. Non-Parametric estimation from incomplete observations. Journal of American Statistical Association 53:457-481, 1958. Cox, D.R., Oakes, D. Analysis of survival data. Chapman and Hill, 1984." adopted and incorporated by reference. The time to graft failure will be determined by the use of insulin post-pancreas transplantation, by the use of dialysis post-renal transplantation, and the use of total parenteral nutrition post-small bowel transplantation. At least ten patients in the appropriate age group must have documented graft function at the end of the one year period to document adequate confidence intervals. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(q) Bone marrow transplantation centers must document, by a current medical literature review, a one-year and a three-year survival rate from patients having received transplantation for the age group, specific diagnosis(es), condition and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(r) The transplant center must provide written recommendations for each client which support the need for the transplant. The recommendations must reflect use of both the transplant center's own patient selection criteria and the Utah Medicaid program criteria as noted in Sections R414-10A-8 through 22. Agreement of the transplant center to provide the required service must also be established.
(s) The physician must provide, for review by the Department, any additional medical information which could affect the outcome of the specific transplant being requested.
(t) The completed request for authorization, along with all required information and documentation, must be delivered to:
Utah Department of Health
Bureau of Coverage and Reimbursement Policy
Utilization Management Unit
Transplant Coordinator
288 North 1460 West
P.O. Box 143103
Salt Lake City, Utah 84114-3103
(u) If incomplete documentation is received by the Department, the client's case is pended until the requested documentation has been received.
(4) Prior authorization for each donor lymphocyte must contain all of the following:
(a) A description of the medical condition that necessitates a donor lymphocyte infusion.
(b) Comprehensive examination, evaluation and recommendations completed by a board-certified or board-eligible specialist in a field directly related to the client's condition that necessitates the transplantation, such as a nephrologist, gastroenterologist, cardiologist, or hematologist. The evaluation must document that the proposed donor lymphocyte infusion for the client is a medically necessary service as defined in Subsections R414-1-2(18)(a) and (b).
(c) Hospital and outpatient records for at least the last six months. If the patient is less than six months of age, the Department requires all case records.
(d) The transplant center must document by a current medical literature review that the donor lymphocyte infusion is a medically necessary service as defined in Subsections R414-1-2(18)(a) and (b) for the age group, specific diagnosis(es), condition, and type of transplantation the client has previously received.
R414-10A-7. Criteria for Transplantation Centers or Facilities.
Transplantation services are covered only in a transplant center or facility which demonstrates the following qualifications to the Department:
(1) Compliance with criteria listed in Sections R414-10A-6 through 22.
(2) The transplant center must document cost effectiveness and quality of service. The transplant center must complete, and submit to the Department for evaluation, documentation specific to the surgical experience of the requesting transplant center, showing applicable one and three year survival rates for all patients receiving transplantation in the last three years. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(3) Out-of-state transplant centers must meet all of the criteria and requirements listed by the Department in Sections R414-10A-6 through 22.
(4) Transplantation services are covered in out-of-state transplant centers only when the service is not available in an approved facility in Utah, and agreement is reached between the Department and the requesting physician that service out-of-state is essential to the individual case.
(5) Reimbursement to out-of-state transplant centers is provided only when the transplant center and the Department can agree upon arrangements which conform to the Department payment methodology.
(6) Corneal transplant facilities must document:
(a) certification or licensure by the Department as an ambulatory surgical center or an acute care general hospital; and
(b) that the surgeon is board-certified or board-eligible in ophthalmology.
(7) Heart, heart lung, intestine, lung, pancreas, kidney, and liver transplant centers must document all of the following:
(a) Current approval by the U.S. Department of Health and Human Services as a Medicare-[
designated]approved center for transplantation of the organ(s) [needed by]requested for the client.(b) Current full membership in the United Network for Organ Sharing for the specific organ transplantation [
needed by]requested for the client.(8) Bone marrow transplant centers must document approval by the National Marrow Donor Program as a bone marrow transplantation center.[
the following:(a) Approval to provide autologous or allogenic bone marrow transplantation from at least one of the following:(i) Children's Cancer Study Group approval as a bone marrow transplantation center for autologous or allogenic bone marrow.(ii) Southwest Oncology Group approval as a bone marrow transplantation center for autologous or allogenic bone marrow.(iii) National Marrow Donor Program approval as a bone marrow transplantation center for allogenic bone marrow.(b) Payment will be made for autologous bone marrow transplantation services only if the transplantation center can document approval by at least one of the agencies named in R414-10A-7(1)through (7), and (8)(a)(i) or (ii) of this rule as an approved autologous bone marrow transplantation center.(c) Payment will be made for allogenic bone marrow transplantation services only if the transplantation center can document approval by at least one of the agencies named in R414-10A-7(1)through (7), and(8)(a)(i) through (iii) of this rule as an approved allogenic bone marrow transplant center.(9) Lung transplant centers must have a current full membership in the United Network for Organ Sharing for lung transplantation.]R414-10A-9. Criteria and Contraindications for Bone Marrow Transplantation.
(1) Bone marrow transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) The client for bone marrow transplantation must meet requirements of Subsections R414-10A-9(2)(a) or (b).
(a) Allogenic and syngeneic bone marrow transplantations may be approved for payment only when the client has an HLA-matched donor. The donor must be compatible for all or a five-out-of-six match of World Health Organization recognized HLA-A, -B, and -DR antigens as determined by appropriate serologic typing methodology.
(i) [
A search of related family members, for a suitable donor, is authorized for payment only after a written prior authorization request has been received by the Department.]The Department authorizes payment for a search of related family members, unrelated persons or both to find a suitable donor.(ii) [
A search of unrelated persons by HLA-type, for a suitable donor, will not be authorized for payment by the Department until the client has been documented to meet all other criteria in this rule for bone marrow transplantation except an HLA-matched donor.(iii)]The transplant center staff must complete, and submit to the Department for evaluation, a current medical literature review, documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year survival rate, or by having a greater than or equal to 55 percent three-year survival rate or by meeting the one-year and three-year survival rates for patients receiving bone marrow transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.(b) Autologous bone marrow [
or peripheral blood stem cell]transplantation performed in conjunction with total body radiation or high dose chemotherapy, may be approved for payment only if a current medical literature review, completed by the transplant center staff and sent to the Department for staff review and evaluation, documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year survival rate, or by having a greater than or equal to 55 percent three-year survival rate or by meeting the one-year and three-year survival rates for patients receiving bone marrow transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.(c) Clients for autologous bone marrow transplantations must have adequate marrow function and no evidence of marrow involvement by the primary malignancy at the time the marrow is harvested.
(3) [
In addition to meeting the requirements of R414-10A-9(2)(a) or (b), the client for bone marrow transplantation must meet the requirements of at least R414-10A-9(3)(a) or (b).(a) The client must have irreversible, progressive bone marrow disease with a life expectancy of one year or less without transplantation or must have greater than a five year increase in life expectancy with transplantation, with no other reasonable medical or surgical alternative to transplantation available.(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a medical literature review documenting that the client's condition will cause irreversible, progressive disease to vital end-organs within two years following the application for transplant and have no other reasonable medical or surgical alternative to transplantation available. The medical literature must also document that the bone marrow transplantation will prevent irreversible, progressive disease to the client's vital end-organs and must document that it will increase the life expectancy of the client by greater than five years. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.(4) In addition to meeting the requirements listed in R414-10A-9, (1) through (3), t]The client for bone marrow transplantation must meet all of the following requirements:(a) Medical assessment that the client is a reasonable risk for surgery with a likelihood of tolerance for immunosuppressive therapy.
(b) Medical assessment by the client's referring physician that the client has sufficient mental, emotional and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long-term follow-up and the immunosuppressive program which is required.
(c) Psycho-social assessment by a board-certified or board-eligible psychiatrist that the client has sufficient mental, emotional and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long-term follow-up and the immunosuppressive program which is required.
(d) The client must have a strong motivation to undergo the procedure as documented by the medical and psycho-social assessment.
(e) If the client has a history of substance abuse, then the client must successfully complete a substance abuse rehabilitation program or must have documented abstinence for a period of at least six months before the Department reviews a request for transplantation services.
(f) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documenting that the underlying original bone marrow disease will not recur and limit survival to less than 75% one-year survival rate, or to less than 55% three-year survival rate. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
([
5]4) Any single contraindication listed below precludes approval for Medicaid payment for bone marrow transplantation:(a) Active infection.
(b) Acute severe hemodynamic compromise at the time of transplantation if accompanied by significant compromise of one or more vital end-organs.
(c) Active substance abuse.
(d) Presence of systemic dysfunction or malignant disease which could limit successful clinical outcome or interfere with compliance with a disciplined medical regimen or rehabilitation after transplantation.
(e) [
Human Immunodeficiency Virus (HIV) antibody positive.(f)]Neuropsychiatric disorder which could lead to non-compliance or inhibit rehabilitation of the patient.([
g]f) Pulmonary diseases:(i) Cystic fibrosis.
(ii) Obstructive pulmonary disease (FEV1 less than 50% of predicted).
(iii) Restrictive pulmonary disease (FVC less than 50% of predicted).
(iv) Unresolved pulmonary roentgenographic abnormalities of unclear etiology.
(v) Recent or unresolved pulmonary infarction.
([
h]g) Cancer, unless treated and eradicated for two or more years or unless a current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documents a greater than or equal to 75% one-year survival rate, or a greater than or equal to 55 percent three-year survival rate, or by meeting the one-year and three-year survival rates after transplantation for the age group, specific cancer, diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
i]h) Cardiovascular diseases:(i) Intractable cardiac arrhythmias.
(ii) Symptomatic or occlusive peripheral vascular or cerebrovascular disease.
(iii) Severe generalized arteriosclerosis.
([
j]i) Evidence of other major organ system disease or anomaly which could decrease the probability of successful clinical outcome or decrease the potential for rehabilitation.([
k]j) Behavior pattern documented in the client's medical or psycho-social assessment which could interfere with a disciplined medical regimen. An indication of non-compliance by the client is documented by any of the following:(i) Non-compliance with medications or therapy.
(ii) Failure to keep scheduled appointments.
(iii) Leaving the hospital against medical advice.
(iv) Active substance abuse.
([
6]5) Prior to the approval of transplantation, the transplantation team must document a plan of care, agreed to by the parent(s) or guardian(s) of a client who is under 18 years of age, to assure compliance to medication and follow-up care, if an indication of non-compliance documented by any of the behaviors listed in Subsections R414-10A-9(5)([k]j)(i) through (iv) is demonstrated by the parent(s) or guardian(s) of the client.(6) The client for donor lymphocyte infusion must produce documentation by current medical literature review and the client's referring physician that the donor lymphocyte infusion is a medically necessary service as defined in Subsections R414-1-2(18)(a) and (b).
R414-10A-10. Criteria and Contraindications for Heart Transplantation.
(1) Heart transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) The client for heart transplantation must meet [
requirements of at least R414-10A-10(2)(a) or (b).(a) The client must have irreversible, progressive heart disease, with a life expectancy of one year or less without transplantation, or documented evidence of progressive pulmonary hypertension, and with no other reasonable medical or surgical alternative to transplantation available.(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a medical literature review documenting that the client's condition will cause irreversible, progressive disease to vital end-organs within two years following the application for transplant and have no other reasonable medical or surgical alternative to transplantation available. The medical literature must also document that the heart transplantation will prevent irreversible, progressive disease to the client's vital end-organs and must document that it will increase the life expectancy of the client by greater than five years. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.(3) In addition to meeting at least one of the requirements listed in R414-10A-10(2), the client must meet]all of the following requirements:(a) The client must have irreversible, progressive heart disease with a life expectancy of one year or less without transplantation, or documented evidence of progressive pulmonary hypertension and no other reasonable medical or surgical alternative to transplantation available.
([
a]b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year survival rate for patients receiving heart transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
b]c) Severe cardiac dysfunction.([
c]d) Medical assessment that the client is a reasonable risk for surgery with a likelihood of tolerance for immunosuppressive therapy.([
d]e) Medical assessment by the client's referring physician that the client has sufficient mental, emotional and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long-term follow-up and the immunosuppressive program which is required.([
e]f) Psycho-social assessment by a board-certified or board-eligible psychiatrist that the client has sufficient mental, emotional and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long-term follow-up and the immunosuppressive program which is required.([
f]g) The client must have strong motivation to undergo the procedure, as documented by the medical and psycho-social assessment.([
g]h) If the client has a history of substance abuse, then the client must successfully complete a substance abuse rehabilitation program or must have documented abstinence for a period of at least six months before the Department reviews a request for transplantation services.([
h]i) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documenting that the underlying original heart disease will not recur and limit survival to less than 75% one-year survival rate. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
4]3) Any single contraindication listed below precludes approval for Medicaid payment for heart transplantation:(a) Active infection.
(b) Acute severe hemodynamic compromise at the time of transplantation if accompanied by significant compromise of one or more non-cardiac vital end-organs.
(c) Active substance abuse.
(d) Presence of systemic dysfunction or malignant disease which could limit successful clinical outcome, interfere with compliance with a disciplined medical regimen or rehabilitation after transplantation.
(e) [
Human Immunodeficiency Virus (HIV) antibody positive.(f)]Neuropsychiatric disorder which could lead to non-compliance or inhibit rehabilitation of the patient.([
g]f) Pulmonary diseases:(i) Cystic fibrosis.
(ii) Obstructive pulmonary disease (FEV1 less than 50% of predicted).
(iii) Restrictive pulmonary disease (FVC less than 50% of predicted).
(iv) Unresolved pulmonary roentgenographic abnormalities of unclear etiology.
(v) Recent or unresolved pulmonary infarction.
([
h]g) Cancer, unless treated and eradicated for two or more years or unless a current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documents a greater than or equal to 75% one-year survival rate after transplantation for the age group, specific cancer, diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
i]h) Cardiovascular diseases:(i) Severe pulmonary hypertension documented in patients 18 years of age and older by a pulmonary vascular resistance greater than eight Wood units, or pulmonary vascular resistance of six or seven Wood units in which a nitroprusside infusion is unable to reduce the pulmonary vascular resistance to less than three Wood units or is unable to reduce the pulmonary artery systolic pressure to below 50 mmHg.
(ii) Severe pulmonary hypertension documented in patients less than 18 years of age and more than six months of age by a pulmonary vascular resistance greater than six pulmonary vascular resistance index units (PVRI), or in which a nitroprusside infusion is unable to reduce the pulmonary vascular resistance to less than six PVRI.
(iii) Symptomatic or occlusive peripheral vascular or cerebrovascular disease.
(iv) Severe generalized arteriosclerosis.
([
j]i) Evidence of other major organ system disease or anomaly which could decrease the probability of successful clinical outcome or decrease the potential for rehabilitation.([
k]j) Behavior pattern documented in the client's medical or psycho-social assessment which could interfere with a disciplined medical regimen. An indication of non-compliance by the client is documented by any of the following:(i) Non-compliance with medications or therapy.
(ii) Failure to keep scheduled appointments.
(iii) Leaving the hospital against medical advice.
(iv) Active substance abuse.
([
5]4) Prior to approval of the transplantation, the transplantation team must document a plan of care, agreed to by the parent(s) or guardian(s), if an indication of non-compliance is demonstrated by the parent(s) or guardian(s) of a client who is under 18 years of age. Non-compliance is demonstrated by documentation of any of the behaviors listed in Subsections R414-10A-10([4]3)([k]j)(i) through (iv).R414-10A-11. Criteria and Contraindications for Intestine Transplantation.
(1) Intestine transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) The client for intestine transplantation must meet [
the requirements of at least R414-10A-11(2)(a) or (b).(a) The client must have irreversible, progressive small bowel and large bowel disease, with a life expectancy of one year or less without transplantation, or must have greater than a five year increase in life expectancy with transplantation, with no other reasonable medical or surgical alternative to transplantation available.(b) The client must have short bowel syndrome that requires daily hyperalimentation with no other reasonable medical or surgical alternative to transplantation available.(3) In addition to meeting at least one of the requirements listed in R414-10A-11(2), the client must meet]all of the following requirements:(a) The client must have short bowel syndrome or irreversible, progressive small bowel disease that requires daily hyperalimentation with no other reasonable medical or surgical alternative to transplantation available.
([
a]b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year small bowel graft function rate for patients receiving intestine transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
b]c) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 85 percent one-year survival rate for patients receiving intestine transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
c]d) Medical assessment that the client is a reasonable risk for surgery with a likelihood of tolerance for immunosuppressive therapy.([
d]e) Medical assessment by the client's referring physician that the client has sufficient mental, emotional and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long term follow up and the immunosuppressive program which is required.([
e]f) Psycho-social assessment by a board-certified or board-eligible psychiatrist that the client has sufficient mental, emotional, and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long-term follow-up and the immunosuppressive program which is required.([
f]g) The client must have a strong motivation to undergo the procedure as documented by the medical and psycho-social assessment.([
g]h) If the client has a history of substance abuse, then he must successfully complete a substance abuse rehabilitation program or must have documented abstinence for a period of at least six months before the Department reviews a request for transplantation services.([
h]i) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documenting that the underlying original intestinal disease will not recur and limit graft function survival to less than 75% one-year survival rate.([
i]j) The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
4]3) Any single contraindication listed below precludes approval for Medicaid payment for small bowel transplantation:(a) Active infection.
(b) Acute severe hemodynamic compromise at the time of transplantation, if accompanied by significant compromise of one or more vital end-organs.
(c) Active substance abuse.
(d) Presence of systemic dysfunction or malignant disease which could limit survival, interfere with compliance with a disciplined medical regimen or rehabilitation after transplantation.
(e) [
Human Immunodeficiency Virus (HIV) antibody positive.(f)]Neuropsychiatric disorder which could lead to non-compliance or inhibit rehabilitation of the patient.([
g]f) Pulmonary diseases:(i) Cystic fibrosis.
(ii) Obstructive pulmonary disease (FEV1 less than 50% of predicted).
(iii) Restrictive pulmonary disease (FVC less than 50% of predicted).
(iv) Unresolved pulmonary roentgenographic abnormalities of unclear etiology.
(v) Recent or unresolved pulmonary infarction.
([
h]g) Cancer, unless treated and eradicated for two or more years, or unless a current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documents a greater than or equal to 85% one-year survival rate after transplantation for the age group, specific cancer, diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
i]h) Cardiovascular diseases:(i) Myocardial infarction within six months.
(ii) Intractable cardiac arrhythmias.
(iii) Class III or IV cardiac dysfunction by New York Heart Association criteria.
(iv) Prior congestive heart failure, unless a cardiovascular consultant determines adequate cardiac reserve.
(v) Symptomatic or occlusive peripheral vascular or cerebrovascular disease.
(vi) Severe generalized arteriosclerosis.
([
j]i) Evidence of other major organ system disease or anomaly which could decrease the probability of successful clinical outcome or decrease the potential for rehabilitation.([
k]j) Behavior pattern documented in the client's medical or psycho-social assessment which could interfere with a disciplined medical regimen. An indication of non-compliance by the client is documented by any of the following:(i) Non-compliance with medications or therapy.
(ii) Failure to keep scheduled appointments.
(iii) Leaving the hospital against medical advice.
(iv) Active substance abuse.
([
5]4) Prior to approval of the transplantation, the transplantation team must document a plan of care, agreed to by the parent(s) or guardian(s), if an indication of non-compliance is demonstrated by the parent(s) or guardian(s) of a client who is under 18 years of age. An indication of non-compliance by the parent(s) or guardian(s) is documented by any of the behaviors listed in Subsections R414-10A-11([4]3)([k]j)(i) through (iv).R414-10A-12. Criteria and Contraindications for Kidney Transplantation.
(1) Kidney transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) All indications for kidney transplantation listed below must be met by each client.
(a) The client must have irreversible, progressive end-stage renal disease.
(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year successful renal graft function rate for patients receiving renal transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(c) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 90 percent one-year survival rate for patients receiving renal transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(d) Medical assessment that the client is a reasonable risk for surgery with a likelihood of tolerance for immunosuppressive therapy.
(e) Medical assessment by the client's referring physician that the client has sufficient mental, emotional and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long-term follow-up and the immunosuppressive program which is required.
(f) Psycho-social assessment by a board-certified or board-eligible psychiatrist that the client has sufficient mental, emotional and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long-term follow-up and the immunosuppressive program which is required.
(g) The client must have strong motivation to undergo the procedure as documented by the medical and psycho-social assessment.
(h) If the client has a history of substance abuse, then the client must successfully complete a substance abuse rehabilitation program or must have documented abstinence for a period of at least six months before the Department reviews a request for transplantation services.
(i) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documenting that the underlying original renal disease will not recur and limit graft function to less than 75% one-year survival rate. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(3) Any single contraindication listed below shall preclude approval for Medicaid payment for kidney transplantation:
(a) Active infection.
(b) Acute severe hemodynamic compromise at the time of transplantation if accompanied by significant compromise of one or more non-renal end-organs.
(c) Active substance abuse.
(d) Presence of systemic dysfunction or malignant disease which could limit successful clinical outcome, interfere with compliance with a disciplined medical regimen or rehabilitation after transplantation.
(e) [
Human Immunodeficiency Virus (HIV) antibody positive.(f)]Neuropsychiatric disorder which could lead to non-compliance or inhibit rehabilitation of the patient.([
g]f) Pulmonary diseases:(i) Cystic fibrosis.
(ii) Obstructive pulmonary disease (FEV1 less than 50% of predicted).
(iii) Restrictive pulmonary disease (FVC less than 50% of predicted).
(iv) Unresolved pulmonary roentgenographic abnormalities of unclear etiology.
(v) Recent pulmonary infarction.
([
h]g) Cancer, unless treated and eradicated for two or more years or unless a current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documents a greater than or equal to 90% one-year survival rate after transplantation for the age group, specific cancer, diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
i]h) Cardiovascular diseases:(i) Myocardial infarction within six months.
(ii) Intractable cardiac arrhythmias.
(iii) Symptomatic or occlusive peripheral vascular or cerebrovascular disease.
(iv) Severe generalized arteriosclerosis.
([
j]i) Evidence of other major organ system disease or anomaly which could decrease the probability of successful clinical outcome or decrease the potential for rehabilitation.([
k]j) Behavior pattern documented in the client's medical or psycho-social assessment which could interfere with a disciplined medical regimen. An indication of non-compliance by the client is documented by any of the following:(i) Non-compliance with medications or therapy.
(ii) Failure to keep scheduled appointments.
(iii) Leaving the hospital against medical advice.
(iv) Active substance abuse.
(4) Prior to approval of the transplantation, the transplantation team must document a plan of care, agreed to by the parent(s) or guardian(s), if an indication of non-compliance is demonstrated by the parent(s) or guardian(s) of a client who is under 18 years of age. An indication of non-compliance by the parent(s) or guardian(s) is documented by any of the behaviors listed in Subsections R414-10A-12(3)([
k]j)(i) through (iv).R414-10A-13. Criteria and Contraindications for Liver Transplantation.
(1) Liver transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) A client for liver transplantation must meet [
requirements of at least R414-10A-13(2)(a) or (b).(a) The client must have irreversible, progressive liver disease with a life expectancy of one year or less without transplantation, with no other reasonable medical or surgical alternative to transplantation available.(b) The transplant center staff must complete, and submit to the Department for review and evaluation, a medical literature review documenting that the client's condition will cause irreversible, progressive disease to vital end-organs within two years following the application for transplant and have no other reasonable medical or surgical alternative to transplantation available. The medical literature must also document that the liver transplantation will prevent the irreversible, progressive disease to the client's vital end-organs and must document that it will increase the life expectancy of the client by greater than five years. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.(3) In addition to meeting the requirements listed in R414-10A-13(2), the client must meet]all of the following requirements:(a) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review, documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year survival rate for patients receiving liver transplantation for the age group, specific diagnosis(es), condition, and type of liver transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(b) Medical assessment that the client is a reasonable risk for surgery with a likelihood of tolerance for immunosuppressive therapy.
(c) Medical assessment by the client's referring physician that the client has sufficient mental, emotional and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long term follow up and the immunosuppressive program which is required.
(d) Psycho-social assessment by a board-certified or board-eligible psychiatrist that the client has sufficient mental, emotional, and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long-term follow-up and the immunosuppressive program which is required.
(e) The client must have a strong motivation to undergo the procedure as documented by the medical and psycho-social assessment.
(f) If the client has a history of substance abuse, then the client must successfully complete a substance abuse rehabilitation program or must have documented abstinence for a period of at least six months before the Department reviews a request for transplantation services.
(g) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documenting that the underlying original liver disease will not recur and limit survival to less than 75% one-year survival rate. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
([
4]3) Any single contraindication listed below precludes approval for Medicaid payment for liver transplantation:(a) Active infection outside the hepatobiliary system.
(b) Acute severe hemodynamic compromise at the time of transplantation, if accompanied by significant compromise of one or more non-hepatic vital end-organs.
(c) Hepatitis B surface antigen positive, except for cases of fulminant hepatitis B.
(d) Stage IV hepatic coma.
(e) Active substance abuse.
(f) Presence of systemic dysfunction or malignant disease which could limit successful clinical outcome, interfere with compliance with a disciplined medical regimen or rehabilitation after transplantation.
(g) [
Human Immunodeficiency Virus (HIV) antibody positive.(h)]Neuropsychiatric disorder which could lead to non-compliance or inhibit rehabilitation of the patient.([
i]h) Pulmonary diseases:(i) Cystic fibrosis.
(ii) Obstructive pulmonary disease (FEV1 less than 50% of predicted).
(iii) Restrictive pulmonary disease (FVC less than 50% of predicted).
(iv) Unresolved pulmonary roentgenographic abnormalities of unclear etiology.
(v) Recent or unresolved pulmonary infarction.
([
j]i) Cancer, unless treated and eradicated for two or more years or unless a current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documents a greater than or equal to 75% one-year survival rate after transplantation for the age group, specific cancer, diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
k]j) Cardiovascular diseases:(i) Myocardial infarction within six months.
(ii) Intractable cardiac arrhythmias.
(iii) Class III or IV cardiac dysfunction by New York Heart Association criteria: "Goldman, L. et al. Comparative reproducibility and validity of systems assessing cardiovascular functional class: Advantages of a new specific activity scale. American Heart Association Circulation 64: 1227, 1981.", adopted and incorporated by reference.
(iv) Prior congestive heart failure, unless a cardiovascular consultant determines adequate cardiac reserve.
(v) Symptomatic or occlusive peripheral vascular or cerebrovascular disease.
(vi) Severe generalized arteriosclerosis.
([
l]k) Evidence of other major organ system disease or anomaly which could decrease the probability of successful clinical outcome or decrease the potential for rehabilitation.([
m]l) Behavior pattern documented in the client's medical or psycho-social assessment which could interfere with a disciplined medical regimen. An indication of non-compliance by the client is documented by any of the following:(i) Non-compliance with medications or therapy.
(ii) Failure to keep scheduled appointments.
(iii) Leaving the hospital against medical advice.
(iv) Active substance abuse.
([
5]4) Prior to approval of the transplantation, the transplantation team must document a plan of care, agreed to by the parent(s) or guardian(s) of a client who is under 18 years of age, to assure compliance with medications and follow-up care, if an indication of non-compliance documented by any of the behaviors listed in Subsections R414-10A-13([4]3)([m]l)(i) through (iv) is demonstrated by the parent(s) or guardian(s) of the client.R414-10A-14. Criteria and Contraindications for Lung Transplantation.
(1) Lung transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) The client for lung transplantation must meet [
requirements of at least R414-10A-14(2)(a) or (b).(a) The client must have end stage lung disease, with a life expectancy of one year or less without transplantation, and with no other reasonable medical or surgical alternative to transplantation available.(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a medical literature review, specific to the client's diagnosis and condition, documenting that the condition will cause irreversible, progressive disease to vital end-organs within two years following the application for transplant and have no other reasonable medical or surgical alternative to transplantation available. The medical literature must also document that the lung transplantation will prevent the irreversible, progressive disease to the client's vital end-organs and must document that it will increase the life expectancy of the client by greater than five years. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.(3) In addition to meeting the requirements listed in R414-10A-14(2), the client must meet]all of the following requirements:(a) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review, documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year survival rate for patients receiving lung transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(b) Medical assessment that the client is a reasonable risk for surgery with a likelihood of tolerance for immunosuppressive therapy.
(c) Medical assessment by the client's referring physician that the client has sufficient mental, emotional and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long term follow up and the immunosuppressive program which is required.
(d) Psycho-social assessment by a board-certified or board-eligible psychiatrist that the client has sufficient mental, emotional, and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long-term follow-up and the immunosuppressive program which is required.
(e) The client must have a strong motivation to undergo the procedure as documented by the medical and psycho-social assessment.
(f) The client with a history of substance abuse must successfully complete a substance abuse rehabilitation program or must have documented abstinence for a period of at least six months before the Department reviews a request for transplantation services.
(g) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documenting that the underlying original lung disease will not recur and limit survival to less than 75% one-year survival rate. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
([
4]3) Any single contraindication listed below shall preclude approval for payment for lung transplantation:(a) Active infection.
(b) Acute severe hemodynamic compromise at the time of transplantation, if accompanied by significant compromise of one or more non-pulmonary vital end-organs.
(c) Active substance abuse.
(d) Presence of systemic dysfunction or malignant disease which could limit survival, interfere with compliance with a disciplined medical regimen or rehabilitation after transplantation.
(e) [
Human Immunodeficiency Virus (HIV) antibody positive.(f)]Neuropsychiatric disorder which could lead to non-compliance or inhibit rehabilitation for the patient.([
g]f) Cancer, unless treated and eradicated for two or more years or unless a current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documents a greater than or equal to 75% one-year survival rate after transplantation for the age group, specific cancer, diagnosis(es), condition and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.(g) Cardiovascular diseases:
(i) Myocardial infarction within six months;
(ii) Intractable cardiac arrhythmias;
(iii) Class III or IV cardiac dysfunction by New York Heart Association criteria.
(iv) Prior congestive heart failure, unless a cardiovascular consultant determines adequate cardiac reserve.
(v) Symptomatic or occlusive peripheral vascular or cerebrovascular disease;
(vi) Severe generalized arteriosclerosis.
([
i]h) Evidence of other major organ system disease or anomaly which could decrease the probability of successful clinical outcome or decrease the potential for rehabilitation.([
j]i) Behavior pattern documented in the client's medical or psycho-social assessment which could interfere with a disciplined medical regimen. An indication of non-compliance by the client is documented by any of the following:(i) Non-compliance with medications or therapy.
(ii) Failure to keep scheduled appointments.
(iii) Leaving the hospital against medical advice.
(iv) Active substance abuse.
([
5]4) Prior to approval of the transplantation, the transplantation team must document a plan of care, agreed to by the parent(s) or guardian(s), if an indication of non-compliance is demonstrated by the parent(s) or guardian(s) of a client who is under 18 years of age. An indication of non-compliance by the parent(s) or guardian(s) is documented by any of the behaviors listed in Subsections R414-10A-14([4]3)([j]i)(i) through (iv).R414-10A-15. Criteria and Contraindications for Pancreas Transplantation.
(1) Pancreas transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) All indications for pancreas transplantation listed below must be met by each client.
(a) The client must have type I diabetes mellitus.
(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a pancreas graft function rate greater than or equal to 75 percent at one-year for patients receiving pancreas transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(c) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 90 percent one-year survival rate for patients receiving pancreas transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(d) Medical assessment that the client is a reasonable risk for surgery with a likelihood of tolerance for immunosuppressive therapy.
(e) Medical assessment by the client's referring physician that the client has sufficient mental, emotional and social stability and support to ensure that he and his parent(s) or guardian(s) will strictly adhere to the long-term follow-up and the immunosuppressive program which is required
(f) Psycho-social assessment by a Board certified psychiatrist that the client has sufficient mental, emotional and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long-term follow-up and the immunosuppressive program which is required.
(g) The client must have strong motivation to undergo the procedure as documented by the medical and psycho-social assessment.
(h) If the client has a history of substance abuse, then he must successfully complete a substance abuse rehabilitation program or must have documented abstinence for a period of at least six months before the Department reviews a request for transplantation services.
(i) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documenting that the underlying original pancreas disease will not recur and limit graft function rate to less than 75% at one-year. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(3) Any single contraindication listed below precludes approval for Medicaid payment for pancreas transplantation:
(a) Active infection.
(b) Acute severe hemodynamic compromise at the time of transplantation if accompanied by significant compromise of one or more end-organs.
(c) Active peptic ulcer.
(d) Active substance abuse.
(e) Presence of systemic dysfunction or malignant disease which could limit successful clinical outcome, interfere with compliance with a disciplined medical regimen or rehabilitation after transplantation.
(f) [
Human Immunodeficiency Virus (HIV) antibody positive.(g)]Irreversible musculoskeletal disease resulting in progressive weakness or in confinement to bed.([
h]g) Neuropsychiatric disorder which could lead to non-compliance or inhibit rehabilitation of the patient.([
i]h) Pulmonary diseases:(i) Cystic fibrosis.
(ii) Obstructive pulmonary disease (FEV1 less than 50% of predictable).
(iii) Restrictive pulmonary disease (FVC less than 50% of predictable).
(iv) Unresolved pulmonary roentgenographic abnormalities of unclear etiology.
(v) Recent pulmonary infarction.
([
j]i) Cancer, unless treated and eradicated for two or more years or unless a current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documents a greater than or equal to 90% one-year survival rate after transplantation for the age group, specific cancer, diagnosis(es), condition and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
k]j) Cardiovascular diseases:(i) Myocardial infarction within six months.
(ii) Intractable cardiac arrhythmias.
(iii) Symptomatic or occlusive peripheral vascular or cerebrovascular disease.
(iv) Severe general arteriosclerosis.
([
l]k) Evidence of other major organ system disease or anomaly which could decrease the probability of successful clinical outcome or decrease the potential for rehabilitation.([
m]l) Behavior pattern documented in the client's medical or psycho-social assessment which could interfere with a disciplined medical regimen. An indication of non-compliance by the client is documented by any of the following:(i) Non-compliance with medications or therapy.
(ii) Failure to keep scheduled appointments.
(iii) Leaving the hospital against medical advice.
(iv) Active substance abuse.
(4) Prior to approval of the transplantation, the transplantation team must document a plan of care, agreed to by the parent(s) or guardian(s), if an indication of non-compliance is demonstrated by the parent(s) or guardian(s) of a client who is under 18 years of age. An indication of non-compliance by the parent(s) or guardian(s) is documented by any of the behaviors listed in Subsections R414-10A-15(3)([
m]l)(i) through (iv).R414-10A-16. Criteria and Contraindications for Small Bowel Transplantation.
(1) Small bowel transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) The client for small bowel transplantation must meet [
requirements of at least R414-10A-16(2)(a) or (b).(a) The client must have irreversible, progressive small bowel disease, with a life expectancy of one year or less without transplantation, or must have greater than a five year increase in life expectancy with transplantation, with no other reasonable medical or surgical alternative to transplantation available.(b) The client must have short bowel syndrome that requires daily total parenteral nutrition with no other reasonable medical or surgical alternative to transplantation available.(3) In addition to meeting one of the requirements listed in R414-10A-16(2), the client must meet]all of the following requirements:(a) The client must have short bowel syndrome or irreversible, progressive small bowel disease that requires daily hyperalimentation with no other reasonable medical or surgical alternative to transplantation available.
([
a]b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year small bowel function rate for patients receiving small bowel transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
b]c) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability for successful clinical outcome by having a greater than or equal to 85 percent one-year survival rate for patients receiving small bowel transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
c]d) Medical assessment that the client is a reasonable risk for surgery with a likelihood of tolerance for immunosuppressive therapy.([
d]e) Medical assessment by the client's referring physician that the client has sufficient mental, emotional and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long term follow up and the immunosuppressive program which is required.([
e]f) Psycho-social assessment by a board-certified or board-eligible psychiatrist that the client has sufficient mental, emotional, and social stability and support to ensure that the client and parent(s) or guardian(s) will strictly adhere to the long-term follow-up and the immunosuppressive program which is required.([
f]g) The client must have a strong motivation to undergo the procedure as documented by the medical and psycho-social assessment.([
g]h) If the client has a history of substance abuse, then he must successfully complete a substance abuse rehabilitation program or must have documented abstinence for a period of at least six months before the Department reviews a request for transplantation services.([
h]i) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documenting that the underlying original small bowel disease will not recur and limit small bowel function survival to less than 85% one-year survival rate.([
i]j) The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
4]3) Any single contraindication listed below shall preclude approval for Medicaid payment for small bowel transplantation:(a) Active infection.
(b) Acute severe hemodynamic compromise at the time of transplantation, if accompanied by significant compromise of one or more vital end-organs.
(c) Active substance abuse.
(d) Presence of systemic dysfunction or malignant disease which could limit survival, interfere with compliance with a disciplined medical regimen or rehabilitation after transplantation.
(e) [
Human Immunodeficiency Virus (HIV) antibody positive.(f)]Neuropsychiatric disorder which could lead to non-compliance or inhibit rehabilitation of the patient.([
g]f) Pulmonary diseases:(i) Cystic fibrosis.
(ii) Obstructive pulmonary disease (FEV1 less than 50% of predicted).
(iii) Restrictive pulmonary disease (FVC less than 50% of predicted).
(iv) Unresolved pulmonary roentgenographic abnormalities of unclear etiology.
(v) Recent or unresolved pulmonary infarction.
([
h]g) Cancer, unless treated and eradicated for two or more years, or unless a current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documents a greater than or equal to 75% one-year survival rate after transplantation for the age group, specific cancer, diagnosis(es), condition and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.([
i]h) Cardiovascular diseases:(i) Myocardial infarction within six months.
(ii) Intractable cardiac arrhythmias.
(iii) Class III or IV cardiac dysfunction by New York Heart Association criteria.
(iv) Prior congestive heart failure, unless a cardiovascular consultant determines adequate cardiac reserve.
(v) Symptomatic or occlusive peripheral vascular or cerebrovascular disease.
(vi) Severe generalized arteriosclerosis.
([
j]i) Evidence of other major organ system disease or anomaly which could decrease the probability of successful clinical outcome or decrease the potential for rehabilitation.([
k]j) Behavior pattern documented in the client's medical or psycho-social assessment which could interfere with a disciplined medical regimen. An indication of non-compliance by the client is documented by any of the following:(i) Non-compliance with medications or therapy.
(ii) Failure to keep scheduled appointments.
(iii) Leaving the hospital against medical advice.
(iv) Active substance abuse.
([
5]4) Prior to approval of the transplantation, the transplantation team must document a plan of care, agreed to by the parent(s) or guardian(s), if an indication of non-compliance is demonstrated by the parent(s) or guardian(s) of a client who is under 18 years of age. An indication of non-compliance by the parent(s) or guardian(s) is documented by any of the behaviors listed in Subsections R414-10A-16(4)(k)(i) through (iv).R414-10A-17. Criteria and Contraindications for Heart and Lung Transplantation.
(1) Heart-lung transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) The client for heart-lung transplantation must meet [
requirements of at least R414-10A-17(2)(a) or (b).(a) The client must have irreversible, progressive heart and lung disease, with a life expectancy of one year or less without transplantation, and with no other reasonable medical or surgical alternative to transplantation available.(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review, documenting that the client's condition will cause irreversible, progressive disease to vital end-organs within two years following the application for transplant and have no other reasonable medical or surgical alternative to transplantation available. The medical literature must also document that the heart-lung transplantation will prevent irreversible, progressive disease to the client's vital end-organs and must document that it will increase the life expectancy of the client by greater than five years. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.(3) In addition to meeting the requirements listed in R414-10A-17(2), the client must meet]all of the following requirements:(a) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review, documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year survival rate for patients receiving heart-lung transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(b) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documenting that the underlying original disease will not recur and limit survival to less than 75% one-year survival rate. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(c) The requirements listed in:
(i) Subsections R414-10A-10(3)(b) through ([
h]i).(ii) Subsections R414-10A-10([
4]3)(a) through ([h]g), and ([j]i) through ([k]j).(iii) Subsection R414-10A-10([
5]4).R414-10A-18. Criteria and Contraindications for Intestine and Liver Transplantation.
(1) Intestine-liver transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) The client for intestine-liver transplantation must meet [
requirements of at least R414-10A-18(2)(a) or (b).(a) The client must have irreversible, progressive liver and intestinal disease, with a life expectancy of one year or less without transplantation, and with no other reasonable medical or surgical alternative to transplantation available.(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting that the condition will cause irreversible, progressive disease to vital end-organs within two years following the application for transplant and have no other reasonable medical or surgical alternative to transplantation available. The medical literature must also document that the intestine-liver transplantation will prevent irreversible, progressive disease to the client's vital end-organs and must document that it will increase the life expectancy of the client by greater than five years. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.(3) In addition to meeting one of the requirements listed in R414-10A-18(2), the client must meet]all of the following requirements:(a) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year small bowel function rate for patients receiving small bowel transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year survival rate for patients receiving intestine-liver transplantation for the age group, specific diagnosis(es), and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(c) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documents that the underlying original disease will not recur and limit survival to less than 75% one-year survival rate. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(d) The requirements listed in:
(i) Subsections R414-10A-13([
3]2)(b) through (g).(ii) Subsections R414-10A-13([
4]3)(a) through ([m]l).(iii) Subsection R414-10A-13([
5]4).R414-10A-19. Criteria and Contraindications for Kidney-Pancreas Transplantation.
(1) Kidney-pancreas transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) The client for kidney-pancreas transplantation must meet [
requirements of at least R414-10A-19(2)(a) or (b).(a) The client must have irreversible, progressive end-stage renal disease and type I diabetes mellitus, with a life expectancy of one year or less without transplantation, and with no other reasonable medical or surgical alternative to transplantation available.(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting that the condition will cause irreversible, progressive disease to vital end-organs within two years following the application for transplant and have no other reasonable medical or surgical alternative to transplantation available. The medical literature must also document that the kidney-pancreas transplantation will prevent irreversible, progressive disease to the client's vital end-organs and must document that it will increase the life expectancy of the client by greater than five years. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.(3) In addition to meeting one of the requirements listed in R414-10A-19(2), the client must meet]all of the following requirements:(a) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year kidney and pancreas function rates for patients receiving kidney-pancreas transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 90 percent one-year survival rate for patients receiving kidney-pancreas transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(c) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documents that the underlying original disease will not recur and limit survival to less than 90% one-year survival rate. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(d) The requirements listed in:
(i) Subsections R414-10A-12(2)(d) through (i).
(ii) Subsections R414-10A-12(3)(a) through ([
k]j).(iii) Subsection R414-10A-12(4).
R414-10A-20. Criteria and Contraindications for Combined Liver-Kidney Transplantation.
(1) Liver-kidney transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) The client for liver-kidney transplantation must meet [
requirements of at least R414-10A-20(2)(a) or (b).(a) The client must have irreversible, progressive liver-kidney disease, with a life expectancy of one year or less without transplantation, and with no other reasonable medical or surgical alternative to transplantation available.(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a medical literature review, specific to the client's diagnosis and condition, documenting that the condition will cause irreversible, progressive disease to vital end-organs within the next two years following the application for transplant and have no other reasonable medical or surgical alternative to transplantation available. The medical literature review must also document that the liver-kidney transplantation will prevent the irreversible, progressive disease to the client's vital end-organs and must document that it will increase the life expectancy of the client by greater than five years. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.(3) In addition to meeting the requirements listed in R414-10A-20(2), the client must meet]all of the following requirements:(a) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review, documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year survival rate for patients receiving liver-kidney transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(b) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documenting a renal graft function rate greater than or equal to 75 percent at one year for patients receiving liver-kidney transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(c) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documenting that the underlying original disease will not recur and limit survival to less than 75% one-year survival rate. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(d) The requirements listed in:
(i) Subsections R414-10A-13([
3]2)(b) through (g).(ii) Subsections R414-10A-13([
4]3)(a) through ([m]l).(iii) Subsection R414-10A-13([
5]4).R414-10A-21. Criteria and Contraindications for Multivisceral Transplantation.
(1) Multivisceral transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) The client for multivisceral transplantation must meet [
requirements of at least R414-10A-21(2)(a) or (b).(a) The client must have irreversible, progressive liver, pancreas and small bowel disease, with a life expectancy of one year or less without transplantation, and with no other reasonable medical or surgical alternative to transplantation available.(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting that the condition will cause irreversible, progressive disease to vital end-organs within two years following the application for transplant and have no other reasonable medical or surgical alternative to transplantation available. The medical literature must also document that the multivisceral transplantation will prevent irreversible, progressive disease to the client's vital end-organs and must document that it will increase the life expectancy of the client by greater than five years. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.(3) In addition to meeting one of the requirements listed in R414-10A-21(2), the client must meet]all of the following requirements:(a) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year pancreas and small bowel function rates for patients receiving multivisceral transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year survival rate for patients receiving multivisceral transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(c) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documents that the underlying original disease will not recur and limit survival to less than 75% one-year survival rate. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(d) The requirements listed in:
(i) Subsections R414-10A-13([
3]2)(b) through (g).(ii) Subsections R414-10A-13([
4]3)(a) through ([m]l).(iii) Subsection R414-10A-13([
5]4).R414-10A-22. Criteria and Contraindications for Liver and Small Bowel Transplantation.
(1) Liver-small bowel transplantation services may be provided for a Medicaid eligible client of any age who meets the following criteria.
(2) The client for liver-small bowel transplantation must meet [
requirements of at least R414-10A-22(2)(a) or (b).(a) The client must have irreversible, progressive liver and small bowel disease, with a life expectancy of one year or less without transplantation, and with no other reasonable medical or surgical alternative to transplantation available.(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting that the client's condition will cause irreversible, progressive disease to vital end-organs within two years following the application for transplant and have no other reasonable medical or surgical alternative to transplantation available. The medical literature must also document that the liver-small bowel transplantation will prevent irreversible, progressive disease to the client's vital end-organs and must document that it will increase the life expectancy of the client by greater than five years. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.(3) In addition to meeting one of the requirements listed in R414-10A-22(2), the client must meet]all of the following requirements:(a) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year small bowel function rate for patients receiving small bowel transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(b) The transplant center staff must complete, and submit to the Department for staff review and evaluation, a current medical literature review documenting a probability of successful clinical outcome by having a greater than or equal to 75 percent one-year survival rate for patients receiving liver-small bowel transplantation for the age group, specific diagnosis(es), condition, and type of transplantation proposed for the client. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(c) A current medical literature review, completed by the transplant center staff and submitted to the Department for staff review and evaluation, documents that the underlying original disease will not recur and limit survival to less than 75% one-year survival rate. The Department shall use independent research by staff medical consultants to evaluate the documentation submitted by the transplant center.
(d) The requirements listed in:
(i) Subsections R414-10A-13([
3]2)(b) through (g).(ii) Subsections R414-10A-13([
4]3)(a) through ([m]l).(iii) Subsection R414-10A-13([
5]4).[
R414-10A-23. Criteria and Contraindications for Other Tissues, Organs, and Multiple Organ Transplantations for Clients Not Specifically Set Forth in This Rule.(1) The Department acknowledges that based on the changing aspect of health care research, numerous individual, combination, multiple tissue or organ transplantations which do not have criteria and contraindications specifically set forth in R414-10A-8 through 22 could conceivably be requested. However, any attempt to set forth all possible tissue and organ transplantation combinations is impractical.(2) The Department shall develop criteria and contraindications for such other individual or combination of nonexperimental or noninvestigational tissue or organ transplantations not specifically set forth in R414-10A-8 through 22, when a request is made on behalf of a client.(3) Development of such new criteria and contraindications shall be based upon existing criteria and contraindication for comparable individual tissue or organ transplantations as set forth in R414-10A-8 through 22 and shall be applied to all clients requesting the new service.(4) Criteria and contraindications for such individual, combination, multiple tissue, or organ transplantations, once established, shall be incorporated into the Utah Administrative Code at R414-10A.]
KEY: Medicaid
Date of Enactment or Last Substantive Amendment: [
March 19, 1998]2007Notice of Continuation: February 2, 2007
Authorizing, and Implemented or Interpreted Law: 26-1-5; 26-18-1
Document Information
- Effective Date:
- 5/9/2007
- Publication Date:
- 04/01/2007
- Filed Date:
- 03/12/2007
- Agencies:
- Health,Health Care Financing, Coverage and Reimbursement Policy
- Rulemaking Authority:
- Authorized By:
- David N. Sundwall, Executive Director
- DAR File No.:
- 29629
- Related Chapter/Rule NO.: (1)
- R414-10A. Transplant Services Standards.